MetaCap

Kyntra Bio (KYNB) vs Exicure (XCUR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kyntra Bio is the larger company by market cap ($6.3 million vs $5.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KYNB-74.55%XCUR-11.75%
+23%-28%-79%
Oct 7, 20261 yearNov 20, 2026
KYNB-74.47%XCUR-14.28%
+11%-34%-79%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KYNB versus XCUR key metrics
MetricKYNBXCUR
Share price$1.56$0.9001
Market cap$6.32M$5.89M
1-day change-13.33%-12.82%
YTD return-82.23%—
1-year return-81.47%—
5-year return-99.49%—
EPS (TTM)$-4.35$-1.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.44M$0
Revenue growth (YoY)-78.26%-100.00%
Net income (latest FY)$183.45M$-4.95M
Gross margin91.37%—
Operating margin-712.66%—
Net margin2848.63%—
52-week high$10.47$9.48
52-week low$1.56$0.777
Distance from 52-week high-85.10%-90.51%
Analyst consensusnone—
Avg. price target upside+2442.95%—
Average volume29.96K53.56K
Shares outstanding4.05M6.55M
Employees341
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Kyntra Bio grew revenue faster in its latest fiscal year (-78.26% vs -100.00%).

About Kyntra Bio

KYNB stock →

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

About Exicure

XCUR stock →

Exicure, Inc. does not have significant operations.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

KYNB vs XCUR FAQ

Which is bigger, Kyntra Bio or Exicure?

Kyntra Bio (KYNB) is larger, with a market capitalization of $6.32M compared with $5.89M for Exicure (XCUR).

Are Kyntra Bio and Exicure in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons